Drug Profile


Alternative Names: Oxycodone/alexopran; Oxycodone/TD-1211; TD-1211/oxycodone

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance Biopharma
  • Class Aza compounds; Benzamides; Cyclohexanes; Heterocyclic bicyclo compounds; Laxatives; Morphine derivatives; Opioid analgesics; Small molecules; Tropanes
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Pain

Most Recent Events

  • 10 Sep 2015 Pharmacokinetics data from a phase I trial in healthy volunteers released by Theravance Biopharma
  • 31 Dec 2014 Theravance Biopharma completes a phase I trial in Pain and opioid induced Constipation (In volunteers) in Australia (PO) (ACTRN12614001152617)
  • 16 Oct 2014 Phase-I clinical trials in Pain in Australia (PO) (ACTRN12614001152617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top